Lymphoma
Conditions
Keywords
Drug Therapy
Brief summary
Participants with CD30-positive lympoma will be treated with brentuximab vedotin according to their clinic's standard practice. The main aim of this study is to collect information on any side effects from treatment with brentuximab vedotin. Other aims are to collect information on how brentuximab vedotin is used to treat these participants and the outcomes of these participants.
Detailed description
This is an observational, non-interventional, prospective study in participants with CD30-positive lymphoma who are receiving or will receive the standard treatment of brentuximab vedotin. This study will assess the safety profile and effectiveness of brentuximab vedotin in the real-world clinical practice. The study will enroll approximately 1000 participants. The data will be collected and recorded in the medical record for the purpose of medical care and also recorded in electronic case report forms (e-CRFs). All the participants will be assigned to a single observational cohort: • All participants with CD30-positive lymphoma This multi-center trial will be conducted in China. All participants will be followed up for 24 months unless withdrawal of Informed Consent, lost or death, whichever comes first. The overall duration of the study will be approximately 4 years.
Interventions
OTHERNo Intervention
This is a non-interventional study.
Sponsors
Takeda
Study design
Observational model
COHORT
Time perspective
PROSPECTIVE
Eligibility
Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No
Inclusion criteria
1. Undergoing treatment with brentuximab vedotin (of less than 3 months from initial treatment with brentuximab vedotin) or to be received with brentuximab vedotin. 2. CD30-positive lymphoma by INV (any CD30 expression)
Exclusion criteria
1\. Who currently participates in or with plan to participate in any interventional clinical trial.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Number of Participants Reporting one or More Serious Adverse Events (SAEs) | Up to 4 years |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Number of Participants Reporting one or More Adverse Events (AEs) | Up to 4 years | — |
| Number of Participants Reporting one or More Adverse Drug Reactions (ADRs) | Up to 4 years | ADRs refers to AE related to administered drug. |
| Number of Participants With Dose Adjustments During the Study | Up to 4 years | — |
| Number of Participants Based on Usage of Brentuximab Vedotin | Up to 4 years | — |
| Number of Cycles of Brentuximub Vedotin Administered in Routine Clinical Practice | Up to 4 years | — |
| Number of Participants Based on Disease Characteristics | Up to 4 years | Number of participants will be reported based on the type of lymphoma, stage, lines of therapy. |
| Time to Next Treatment (TTNT) | From start of each line of therapy until next line of therapy (up to 4 years) | TTNT is defined as time between start of each line of a therapy to the next line of therapy. |
| Objective Response Rate (ORR) | Up to 4 years | ORR is defined as the percentage of participants with complete response (CR) and partial response (PR) after treatment in the total number of assessable cases. |
| Duration of Response (DOR) | From date of first documented CR until PD (up to 4 years) | DOR is calculated from the time of documentation of a CR to documentation of disease progression. CR is defined as disappearance of all residual disease and tumor lesions. Disease progression (PD) is defined as at least a 20% increase in the sum of the longest diameter (LD) of target lesions, taking as reference the smallest sum LD recorded since the treatment started or the appearance of one or more new lesions. |
| Progression Free Survival (PFS) Rate | 1 year and 2 years | PFS rate is calculated as the percentage of participants who reported PFS (at 1st year, 2nd year) as per investigator's assessment after brentuximab vedotin treatment. |
| Overall Survival (OS) Rate | 1 year and 2 years | OS rate is measured as the percentage of participants who reported death (at 1st year, 2nd year) after brentuximab vedotin treatment. |
| Change From Baseline in Quality of Life (QoL) Assessed Using Functional Assessment of Cancer Therapy Lymphoma (FACT-Lym) Questionnaire Version 4 | Up to 4 years | The FACT-Lym questionnaire is a validated instrument for assessing the impact of lymphoma on health related quality of life and contains 42 questions covering health related quality of life, common lymphoma symptoms, and treatment side-effects. It contains four core subscales including: Physical Wellbeing, Social/Family Wellbeing, Emotional Wellbeing, and Functional Wellbeing. All questions are answered on a 5-point likert scale ranging from 0 to 4: 0=not at all,1=a little bit, 2=somewhat, 3=quite a bit, 4=very much. Higher scores are associated with a better quality of life. |
| Cost-effectiveness Ratio | Up to 4 years | Cost-effectiveness ratio will be assessed by the direct cost (including medication, injunction, test, nursing fee, etc.) under brentuximab vedotin treatment divided by the total percent of CR and PR. |
Countries
China
Contacts
STUDY_DIRECTORStudy Director
Takeda
Outcome results
None listed